The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…
BUSINESS
Rakuten Medical’s Photoimmunotherapy Now Available in Japan
Rakuten Medical Japan said on February 8 that it has launched its photoimmunotherapy agent Akalux (cetuximab sarotalocan sodium) along with a laser system called BioBlade for the treatment of unresectable locally advanced or recurrent head and neck cancer. Akalux is…
To read the full story
Related Article
- Rakuten Medical Ratcheting Up Overseas Expansion Drive for Akalux: Japan Chief
April 25, 2024
- Rakuten Medical Gears Up for Global Pitch on Photoimmunotherapy: Chairman
August 4, 2023
- Rakuten Medical Eyes Label Expansion for Photoimmunotherapy, Asia as Key Market
August 26, 2021
- Medipal to Take on Akalux Distribution in Japan, Rakuten’s Photoimmunotherapy
January 13, 2021
- After Photoimmunotherapy Nod, Rakuten’s Mikitani Says Company Is Finally at Start Line
September 30, 2020
- Rakuten Medical’s Photoimmunotherapy Filed in Japan, Subject to Conditional Early OK
July 1, 2020
- Mikitani Resolved to Grow Rakuten Medical into Global Biotech
July 2, 2019
- Rakuten Medical Could File Photoimmunotherapy for Head and Neck Cancer in 2022; COO Says More Indications Eyed
June 12, 2019
BUSINESS
- Takeda to Halt Sales of Cell Therapy Alofisel in Japan
January 15, 2026
- Rohto to Roll Out 3- or 4-Day Workweek Option from April to Spur Growth, Retention
January 15, 2026
- Rakuten Joins Hands with LOTTE Biologics to Boost Production for Photoimmunotherapy
January 15, 2026
- Daiichi Sankyo Unveils Brand Site for OTC NorLevo Ahead of Launch
January 15, 2026
- Cheplapharm to Take Over Japan MA for UCB’s Myocalm
January 15, 2026
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…